Home Categories Send inquiry

(S)-3-Amino-3-Phenylpropan-1-ol CAS 82769-76-4 Purity: ≥98.0% Factory Dapoxetine Hydrochloride Intermediate

Commercial Supply Dapoxetine Hydrochloride and Related Intermediates: 3-Chloropropiophenone CAS: 936-59-4 (S)-3-Amino-3-Phenylpropan-1-ol CAS: 82769-76-4 (S)-3-Amino-3-Phenylpropanoic Acid CAS: 40856-44-8 (R)-Diphenylprolinol CAS: 22348-32-9 (S)-Diphenylprolinol CAS: 112068-01-6 (S)-(-)-3-Chloro-1-Phenyl-1-Propanol CAS: 100306-34-1 Dapoxetine Hydrochloride CAS: 129938-20-1
Chemical Name (S)-3-Amino-3-Phenylpropan-1-ol
Synonyms (S)-3-Amino-3-Phenyl-1-propanol; (S)-1-Phenyl-3-Propanolamine
CAS Number 82769-76-4
CAT Number RF-PI153
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C9H13NO
Molecular Weight 151.21
Melting Point 68.0~69.0℃
Boiling Point 273.23°C at 760 mmHg
Density 1.0406 g/cm3
Shipping Condition Shipped Under Ambient Temperature
Brand Ruifu Chemical
Item Specifications
Appearance White to Off-White Crystalline/Colorless to Pale Yellow Oily Liquid
Purity ≥98.0%
Loss on Drying ≤0.50%
Specific Rotation [α]D20 -22.0°~ -26.0° (C=1 in CHCl3)
Test Standard Enterprise Standard
Usage Dapoxetine Hydrochloride Pharmaceutical Intermediate 
Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation. Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (S)-3-Amino-3-Phenylpropan-1-ol (CAS: 82769-76-4) with high quality, widely used in organic synthesis, synthesis of pharmaceutical intermediates and active pharmaceutical ingredient (API) synthesis. (S)-3-Amino-3-Phenylpropan-1-ol (CAS: 82769-76-4) can be used in the synthesis of Dapoxetine Hydrochloride (CAS: 129938-20-1). Dapoxetine Hydrochloride is a short-acting novel selective serotonin reuptake inhibitor marketed for the treatment of premature ejaculation in men. Premature ejaculation (PE) is the most common male sexual disorder, estimated to affect up to 30% of men.